Diffuse Scleroderma clinical trials at University of California Health

14 in progress, 5 open to eligible people

Showing trials for

  • Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease

    open to eligible people ages 18 years and up

    This study investigates the efficacy and safety of belimumab compared to placebo, in addition to standard therapy, for the treatment of participants with systemic sclerosis associated interstitial lung disease (SSc-ILD). The study will evaluate the effect of belimumab treatment on lung function as well as on extra-pulmonary disease manifestations, including skin thickening and general symptoms, such as fatigue, that impact quality of life (QoL).

    at UCLA

  • CTX112 in Adult Subjects With Refractory Autoimmune Disease

    open to eligible people ages 18-70

    This is a single-arm, open-label, multicenter, ascending dose Phase 1 study evaluating the safety and preliminary efficacy of CTX112 in adult subjects with refractory autoimmune diseases, including active systemic lupus erythematosus (SLE), systemic sclerosis (SSc), or idiopathic inflammatory myopathy (IIM).

    at UCSD

  • EncompaSSc: Evaluation of MTX-474 in Participants With Diffuse Cutaneous Systemic Sclerosis (dcSSc)

    open to eligible people ages 18 years and up

    A Phase 2 Randomized, Double-blind, Placebo-Controlled Study of the Safety and Efficacy of MTX-474 in Participants with Diffuse Cutaneous Systemic Sclerosis (dcSSc)

    at UCLA

  • Long-term Safety and Efficacy of Belimumab in Adults With Interstitial Lung Disease (ILD) Associated With Systemic Sclerosis (SSc) and Other Connective Tissue Diseases (CTD) (BLISSconneCTD-OLE)

    open to eligible people ages 18 years and up

    This is an open label extension (OLE) study of an ongoing randomized controlled parent clinical studies 218224 (NCT05878717) and 221672 (NCT06572384) which aim to assess the efficacy and safety of belimumab on reducing the decline in lung function in participants with interstitial lung disease associated with diffuse cutaneous systemic sclerosis (dcSSc-ILD) and interstitial lung disease associated with other connective tissue diseases (CTD-ILD), respectively. The OLE study will describe how well tolerated belimumab will be long term, and whether it might continue to slow progression of lung function decline, slow overall disease progression and improve quality of life.

    at UCLA

  • NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)

    open to eligible people ages 18-75

    This is a Phase 1/2, open-label, multi-center, multi-cohort, non-randomized dose escalation and dose expansion basket study to determine the safety and tolerability of NKX019 (allogeneic CAR NK cells targeting CD19) in participants with autoimmune diseases.

    at UC Irvine

  • Preliminary Efficacy of EHP-101 in Diffuse Cutaneous Systemic Sclerosis

    Sorry, currently not accepting new patients, but might later

    The purpose of this trial is to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of EHP-101 in adult subjects with diffuse cutaneous Systemic Sclerosis (dcSSc).

    at UCLA

  • BMS-986278 in Participants With Progressive Pulmonary Fibrosis

    Sorry, in progress, not accepting new patients

    The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis.

    at UC Irvine UCLA UCSF

  • CNTY-101 in Participants With Refractory B Cell-mediated Autoimmune Diseases

    Sorry, in progress, not accepting new patients

    CALiPSO-1 is a Phase 1, multi-centre, dose-confirmation study to evaluate the safety and efficacy of CNTY-101 in participants with refractory B cell-mediated autoimmune diseases including those with moderate to severe systemic lupus erythematosus (SLE) with or without lupus nephritis (LN), idiopathic inflammatory myopathies (IIM), and diffuse cutaneous systemic sclerosis (DcSSc).

    at UC Davis

  • Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)

    Sorry, in progress, not accepting new patients

    The purpose of this study is to evaluate the efficacy and safety of treatment with subcutaneous anifrolumab versus placebo in adult participants with systemic sclerosis. The target population for this study includes patients who meet the 2013 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) classification for systemic sclerosis, either limited or diffuse cutaneous subsets, with a disease duration of less than 6 years from first non-Raynaud's phenomenon symptom.

    at UCLA

  • Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis

    Sorry, in progress, not accepting new patients

    The purpose of this study is to evaluate efficacy, safety and tolerability of s.c. ianalumab administered in participants with diffuse cutaneous systemic sclerosis relative to placebo

    at UCLA

  • Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension

    Sorry, in progress, not accepting new patients

    The purpose of this phase 2 multicenter, randomized, double-blind, placebo-controlled, study is to assess the safety and efficacy of ifetroban in patients with diffuse cutaneous systemic SSc (dcSSc) or SSc-associated pulmonary arterial hypertension (SSc-PAH).

    at UCLA

  • Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis

    Sorry, in progress, not accepting new patients

    The purpose of this study is to evaluate the efficacy, safety and tolerability of rapcabtagene autoleucel (administered once following lymphodepletion) in participants with severe refractory diffuse cutaneous systemic sclerosis relative to rituximab.

    at UCLA UCSF

  • Tibulizumab Systemic Sclerosis Understanding and Response Evaluation (TibuSURE)

    Sorry, in progress, not accepting new patients

    The study is a Phase 2, multi-center, randomized, double-blind, placebo-controlled study to evaluate the effects of tibulizumab over 24 weeks (Period 1) in adult participants with systemic sclerosis, followed by an open-label extension period where all active participants will receive tibulizumab and will be evaluated for an additional 28 weeks (Period 2)

    at UCLA UCSD

  • Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)

    Sorry, in progress, not accepting new patients

    The purpose of this study is to assess the safety and efficacy of tulisokibart in participants with SSc-ILD.

    at UCLA

Our lead scientists for Diffuse Scleroderma research studies include .

Last updated: